10 news items
NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
NKGN
12 Jun 24
as planned including delays in timing, format, or accessibility; and NKGen's ability to raise additional funding to complete the development of its product
NKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
NKGN
3 Jun 24
, or accessibility; and NKGen's ability to raise additional funding to complete the development of its product candidates. These and other risks
Spotlighting Unexplored Stocks in Focus: NKGN, INBS, BTBT, PRSO, MGOL
BTBT
INBS
MGOL
24 May 24
earnings surprise. CEO and CFO will present at a virtual conference on May 30, offering investors access to webcast materials on the company's site
NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
NKGN
23 May 24
will not be published as planned including delays in timing, format, or accessibility; and NKGen's ability to raise additional funding to complete the development
NKGen Biotech's SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer's Disease
NKGN
20 May 24
will not be completed as planned; the risk that the abstract will not be published as planned including delays in timing, format, or accessibility; and NKGen's
jfe182 rz
NKGN
16 May 24
, or accessibility; and NKGen's ability to raise additional funding to complete the development of its product candidates. These and other risks and uncertainties
0bcramifo59hnuqdh5f4tzt2v6m17s 84j
NKGN
25 Apr 24
as planned including delays in timing, format, or accessibility; and NKGen's ability to raise additional funding to complete the development of its
g1l4h3
NKGN
24 Apr 24
will not be published as planned including delays in timing, format, or accessibility; and NKGen's ability to raise additional funding to complete the development
aahrkdshbejnb2r
NKGN
11 Apr 24
will not be completed as planned; the risk that the abstract will not be published as planned including delays in timing, format, or accessibility; and NKGen's
ca1lmy33ounz d0z99ukkfzkb0mw1f36o3s0d21p0qpwsq2z2
NKGN
25 Mar 24
; the risk that the abstract will not be published as planned including delays in timing, format, or accessibility; and NKGen's ability to raise additional
- Prev
- 1
- Next